Coherus BioSciences (CHRS) Misses Q1 EPS by 205c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.46 -1.35%
Revenue Growth %: +91.8%
Financial Fact:
Occupancy and buying expenses: 81.34M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +91.8%
Financial Fact:
Occupancy and buying expenses: 81.34M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.35), $2.05 worse than the analyst estimate of $1.70. Revenue for the quarter came in at $7.6 million versus the consensus estimate of $54.36 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- MSCI upgrades Bulgaria to Frontier, flags Indonesia and Turkey risks
- Boeing wins $2 billion satellite contract from DoW
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
